{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDG+PET%2FMRI&page=2", "query": { "intervention": "FDG PET/MRI", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDG+PET%2FMRI&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T06:45:39.313Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05054998", "title": "Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-08-03", "completion_date": "2024-04-26", "has_results": false, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054998" }, { "nct_id": "NCT06814587", "title": "Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease", "Coronary Artery Bypass Graft (CABG)" ], "interventions": [ { "name": "Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)", "type": "DIAGNOSTIC_TEST" }, { "name": "[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)", "type": "DIAGNOSTIC_TEST" }, { "name": "SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "20 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2024-07-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06814587" }, { "nct_id": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Chronic Lymphocytic Lymphoma", "B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "CT Scan chest/abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "18-FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-12-16", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599634" }, { "nct_id": "NCT07021989", "title": "ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma, Adult", "Refractory Hodgkin Lymphoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Non-investigational, involved site radiotherapy (ISRT)", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Foresight CLARITY™ LDT", "type": "DEVICE" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE", "PROCEDURE" ], "sponsor": "Michael Spinner, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2026-08-18", "completion_date": "2034-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 6, "location_summary": "Davis, California • Fresno, California • Irvine, California + 3 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07021989" }, { "nct_id": "NCT02070406", "title": "Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL", "type": "BIOLOGICAL" }, { "name": "dendritic cell vaccine therapy", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 4, "start_date": "2014-07-17", "completion_date": "2018-12-18", "has_results": false, "last_update_posted_date": "2019-02-28", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02070406" }, { "nct_id": "NCT01283178", "title": "Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Salivary Gland Squamous Cell Carcinoma", "Stage II Salivary Gland Cancer", "Stage II Squamous Cell Carcinoma of the Hypopharynx", "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage II Squamous Cell Carcinoma of the Oropharynx", "Stage II Verrucous Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "image-guided adaptive radiation therapy", "type": "RADIATION" }, { "name": "3'-deoxy-3'-[18F]fluorothymidine", "type": "OTHER" }, { "name": "positron emission tomography/computed tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 3, "start_date": "2011-07", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283178" }, { "nct_id": "NCT02405078", "title": "Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2015-10-13", "completion_date": "2022-10-03", "has_results": false, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405078" }, { "nct_id": "NCT04754581", "title": "Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Maximal ATP Production (ATPmax)", "type": "OTHER" }, { "name": "Exercise Testing (VO2max)", "type": "OTHER" }, { "name": "Muscle Biopsy", "type": "PROCEDURE" }, { "name": "Adipose Tissue Biopsy", "type": "PROCEDURE" }, { "name": "Hyperinsulinemic euglycemic clamp", "type": "OTHER" }, { "name": "PET imaging", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "AdventHealth Translational Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "30 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2021-03-30", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04754581" }, { "nct_id": "NCT00564733", "title": "FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Effusion", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "imaging biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2007-10", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00564733" }, { "nct_id": "NCT00095693", "title": "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Recurrent Thyroid Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2014-01-16", "last_synced_at": "2026-09-24T06:45:39.313Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095693" } ] }